Related Experiment Video

Updated: Oct 4, 2025

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.9K

Observational study of inhaled corticosteroid treatment for improved expiratory variability index in steroid-naïve

Janne Burman1, Pekka Malmberg1, Ville-Pekka Seppä2

  • 1Dept of Allergology, Helsinki University and University Hospital of Helsinki, Skin and Allergy Hospital, Helsinki, Finland.

ERJ Open Research
|February 10, 2022
PubMed

Insights

Inhaled corticosteroid treatment significantly improved expiratory variability in young children with asthma who had not previously used steroids. This finding highlights early treatment benefits for respiratory control in pediatric asthma.

Area of Science:

  • Pediatric Pulmonology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Asthma is a common chronic respiratory disease in children.
  • Early intervention in pediatric asthma is crucial for long-term outcomes.
  • Steroid-naïve children represent a specific population for treatment efficacy studies.

Purpose of the Study:

  • To evaluate the effect of inhaled corticosteroid (ICS) treatment on expiratory airflow dynamics.
  • To assess treatment efficacy in steroid-naïve asthmatic children aged 4-7 years.
  • To determine if ICS improve measures of expiratory variability.

Main Methods:

  • A cohort of steroid-naïve children aged 4-7 years with asthma was studied.
  • Participants received inhaled corticosteroid treatment.
  • Expiratory variability index (EVI) was measured before and after treatment initiation.

Main Results:

  • Inhaled corticosteroid treatment led to a significant improvement in the expiratory variability index.
  • The positive effect was observed in the target age group of 4-7 years.
  • No prior steroid use was a key characteristic of the study population.

Conclusions:

  • Inhaled corticosteroids are effective in improving expiratory variability in young, steroid-naïve asthmatic children.
  • Early initiation of ICS treatment may benefit respiratory control in this population.
  • Findings support the use of ICS for managing early-stage pediatric asthma.

More Related Videos

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples11:54

Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples

Published on: January 21, 2018

31.0K
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

9.9K

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
451
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
433
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.7K
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
452
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.2K